127 related articles for article (PubMed ID: 31958446)
1. Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial.
Noronha V; Bhattacharjee A; Patil VM; Joshi A; Menon N; Shah S; Kannan S; Mukadam SA; Maske K; Ishi S; Prabhash K
Chest; 2020 Jun; 157(6):1647-1655. PubMed ID: 31958446
[TBL] [Abstract][Full Text] [Related]
2. Aprepitant for Cough in Lung Cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights.
Smith JA; Harle A; Dockry R; Holt K; Russell P; Molassiotis A; Yorke J; Robinson R; Birrell MA; Belvisi MG; Blackhall F
Am J Respir Crit Care Med; 2021 Mar; 203(6):737-745. PubMed ID: 32966755
[No Abstract] [Full Text] [Related]
3. The Neurokinin-1 Receptor Antagonist Orvepitant Is a Novel Antitussive Therapy for Chronic Refractory Cough: Results From a Phase 2 Pilot Study (VOLCANO-1).
Smith J; Allman D; Badri H; Miller R; Morris J; Satia I; Wood A; K Trower M
Chest; 2020 Jan; 157(1):111-118. PubMed ID: 31421110
[TBL] [Abstract][Full Text] [Related]
4. Emerging targets for cough therapies; NK1 receptor antagonists.
Badri H; Smith JA
Pulm Pharmacol Ther; 2019 Dec; 59():101853. PubMed ID: 31622673
[TBL] [Abstract][Full Text] [Related]
5. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
Hirsh V; Cadranel J; Cong XJ; Fairclough D; Finnern HW; Lorence RM; Miller VA; Palmer M; Yang JC
J Thorac Oncol; 2013 Feb; 8(2):229-37. PubMed ID: 23328549
[TBL] [Abstract][Full Text] [Related]
6. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Chen Y; Zhou J; Wang D
Lung Cancer; 2018 Aug; 122():32-37. PubMed ID: 30032842
[TBL] [Abstract][Full Text] [Related]
7. Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU).
Tsianakas A; Zeidler C; Riepe C; Borowski M; Forner C; Gerss J; Metz M; Staubach P; Raap U; Kaatz M; Urban M; Luger TA; Ständer S
Acta Derm Venereol; 2019 Apr; 99(4):379-385. PubMed ID: 30653242
[TBL] [Abstract][Full Text] [Related]
8. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Bezjak A; Tu D; Seymour L; Clark G; Trajkovic A; Zukin M; Ayoub J; Lago S; de Albuquerque Ribeiro R; Gerogianni A; Cyjon A; Noble J; Laberge F; Chan RT; Fenton D; von Pawel J; Reck M; Shepherd FA;
J Clin Oncol; 2006 Aug; 24(24):3831-7. PubMed ID: 16921034
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.
Kusagaya H; Inui N; Karayama M; Fujisawa T; Enomoto N; Kuroishi S; Nakamura Y; Matsuda H; Yokomura K; Koshimizu N; Toyoshima M; Imokawa S; Yamada T; Shirai T; Hayakawa H; Suda T
Lung Cancer; 2015 Dec; 90(3):410-6. PubMed ID: 26791800
[TBL] [Abstract][Full Text] [Related]
10. Phase III Randomized Trial of Palonosetron and Dexamethasone With or Without Aprepitant to Prevent Nausea and Vomiting Induced by Full-dose Single-day Cisplatin-based Chemotherapy in Lung Cancer.
Wu F; Lin X; Yang Z; Sun Z; Zeng F; Heng J; Qu J; Zeng L; Yang N; Zhang Y
Clin Lung Cancer; 2018 Nov; 19(6):e913-e918. PubMed ID: 30197265
[TBL] [Abstract][Full Text] [Related]
11. Neurokinin-1 Receptor Inhibition and Cough.
Turner RD; Birring SS
Am J Respir Crit Care Med; 2021 Mar; 203(6):672-674. PubMed ID: 33108214
[No Abstract] [Full Text] [Related]
12. Cough in Patients With Lung Cancer: A Longitudinal Observational Study of Characterization and Clinical Associations.
Harle ASM; Blackhall FH; Molassiotis A; Yorke J; Dockry R; Holt KJ; Yuill D; Baker K; Smith JA
Chest; 2019 Jan; 155(1):103-113. PubMed ID: 30321508
[TBL] [Abstract][Full Text] [Related]
13. Inhaled sodium cromoglycate to treat cough in advanced lung cancer patients.
Moroni M; Porta C; Gualtieri G; Nastasi G; Tinelli C
Br J Cancer; 1996 Jul; 74(2):309-11. PubMed ID: 8688342
[TBL] [Abstract][Full Text] [Related]
14. Why Use Aprepitant Only as a Cough Suppressant in Lung Cancer When at Higher Doses it Could Also Exert an Antitumor Action?
Muñoz M; Muñoz ME; Morell F; Coveñas R
Arch Bronconeumol; 2022 Oct; 58(10):727-728. PubMed ID: 35606264
[No Abstract] [Full Text] [Related]
15. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study.
Santini D; Vincenzi B; Guida FM; Imperatori M; Schiavon G; Venditti O; Frezza AM; Berti P; Tonini G
Lancet Oncol; 2012 Oct; 13(10):1020-4. PubMed ID: 22995650
[TBL] [Abstract][Full Text] [Related]
16. Benzonatate for opioid-resistant cough in advanced cancer.
Doona M; Walsh D
Palliat Med; 1998 Jan; 12(1):55-8. PubMed ID: 9616460
[TBL] [Abstract][Full Text] [Related]
17. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
[TBL] [Abstract][Full Text] [Related]
18. Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
Califano R; Griffiths R; Lorigan P; Ashcroft L; Taylor P; Burt P; Lee L; Chittalia A; Harris M; Faivre-Finn C; Thatcher N; Blackhall F
Lung Cancer; 2011 Sep; 73(3):338-44. PubMed ID: 21296449
[TBL] [Abstract][Full Text] [Related]
19. Validation of the Japanese version of the Manchester Cough in Lung Cancer Scale.
Kishimoto Y; Shirai T; Akamatsu T; Suzuki T; Asada K; Kanemitsu Y; Niimi A
Respir Investig; 2021 Nov; 59(6):865-870. PubMed ID: 34001459
[TBL] [Abstract][Full Text] [Related]
20. A cross sectional study to determine the prevalence of cough and its impact in patients with lung cancer: a patient unmet need.
Harle A; Molassiotis A; Buffin O; Burnham J; Smith J; Yorke J; Blackhall FH
BMC Cancer; 2020 Jan; 20(1):9. PubMed ID: 31906892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
